Generate Biomedicines, Inc. Sets Initial Public Offering at $16.00 per Share Generate Biomedicines, Inc. announces its IPO pricing at $16 per share. The company aims to raise $400 million to advance its innovative biotechnology efforts.

Generate Biomedicines, Inc. Sets Initial Public Offering at $16.00 per Share #United_States #Somerville #Initial_Public_Offering #Generate_Biomedicines #Nasdaq_GENB

Generate Biomedicines Launches Global Phase 3 Trials for GB-0895, an Innovative Long-Acting Anti-TSLP Antibody Designed to Treat Severe Asthma Generate Biomedicines has announced the initiation of global Phase 3 clinical trials for GB-0895, an innovative long-acting antibody aimed at severe asthma treatment.

Generate Biomedicines Launches Global Phase 3 Trials for GB-0895, an Innovative Long-Acting Anti-TSLP Antibody Designed to Treat Severe Asthma #USA #Somerville #GB-0895 #Generate_Biomedicines #asthma